All probes

ML203 : PKM (Pyruvate Kinase M2) Activator

ML203

ML203

Target Name

Pyruvate Kinase M2

Target Alias

PKM

Target Class

Kinase

Mechanism of Action

Activator of PKM

Biological / Disease Relevance

Metabolism, Cancer Metabolism

In vitro activity
hPyk-M2 bioassay (EC50)
129 nM
In vitro activity
LDH Secondary Assay (EC50)
92 nM

Target Information

The expression of human pyruvate kinase M2 (hPK-M2) in cancer cells appears to be critical for tumor cell growth and proliferation in vivo. Because the PK-M2 isoform is expressed in all cancer cells studied, it represents a target for drug development that could potentially enable tumor cells to return to a normal state of metabolism. If this novel strategy for targeting malignancy were successful, it would be applicable to diverse types of cancer. The probe ML203 (CID-44543605) is a member of a series of highly specific allosteric activators for the tumor-specific isoform of human pyruvate kinase (M2 isoform). The probe affects the cooperativity of phosphoenolpyruvate (PEP) binding, with little affect on adenosine diphosphate (ADP) binding, in a manner similar to Fructose-1,6-bisphosphate (FBP).

Project Team

Properties

ML203

DASA-58

Physical & chemical properties
Molecular Weight 453.5 g/mol
Molecular Formula C19H23N3O6S2
cLogP 1.1
PSA 136 Ų
Storage
Solubility 29 ug/mL in PBS, pH 7.4, 23C; 10 mM in DMSO
CAS Number 1203494-49-8

SMILES:
NC1=CC(S(=O)(N2CCCN(S(=O)(C3=CC4=C(OCCO4)C=C3)=O)CC2)=O)=CC=C1

InChI:
InChI=1S/C19H23N3O6S2/c20-15-3-1-4-16(13-15)29(23,24)21-7-2-8-22(10-9-21)30(25,26)17-5-6-18-19(14-17)28-12-11-27-18/h1,3-6,13-14H,2,7-12,20H2

InChIKey:
GMHIOMMKSMSRLY-UHFFFAOYSA-N

Activity

In vitro activity - Selectivity Assays

ML203 (EC50)

hPyk-M2

129 nM

LDH kinetic assay

92 nM

hPyk-M1

Inactive

hPyk-R

Inactive

hPyk-L

Inactive

Summary /

ML203 is observed to be selective and potent (with > 100 fold selectivity) against hPyk-M2. This probe is also active in the confirmatory LDH assay; a kinetic mode assay generated by coupling the generation of pyruvate by pyruvate kinase to the depletion of NADH through lactate dehydrogenase. It is found to be inactive against the human Reticulocyte Pyruvate Kinase (hPyk-R), Pyruvate Kinase M1 Isoform (hPyk-M1), and Liver Pyruvate Kinase (hPyk-L).

 

Figure 1. Dose response curves for NCGC00185916/ CID_44543605/ ML203 against the four hPyk isozymes.

In vitro assay - Mechanism of Action Studies

Summary /

The mode of action for the probe versus hPykM2 is assessed through analysis of the steady-state kinetics of PEP and ADP by the hPykM2. Fructose-1,6-bisphosphate is known to allosterically activate hPykM2 through induction of an enzyme state with a high affinity for PEP. In the absence of any of these activators, hPyk shows low affinity for PEP (KM ~ 1.5mM). In the presence of NCGC00031955 (CID_654376, SID_851783) or NCGC00030335 (CID_650361, SID_847943) or FBP, the KM for PEP decreased 10-fold to 0.13±0.04 mM or 0.1±0.02 mM for the two activators, respectively, with lesser effects on Vmax (values of 245 pmols/min with or without FBP and 255 pmols/min with NCGC00031955: CID_654376, SID_851783). In contrast, variation of the concentration of ADP in the presence and absence of activators shows that the steady-state kinetics are not significantly affected (KM for ADP = 0.1mM in either condition). Thus, NCGC00031955 (CID_654376, SID_851783) and NCGC00030335 (CID_650361, SID_847943) activate hPykM2by increasing the enzyme’s affinity for PEP and have little effect on ADP kinetics. This is similar to what we observed for FBP, which agrees with previous reports demonstrating increased affinity for PEP as the reason for activation of hPykM2 by FBP.